Preclinical Alzheimer Disease Is Not Significantly Affected by Solanezumab.

Published Date: 19 Oct 2023

Based on the primary or secondary cognitive and functional end points over a 4–5 year treatment period, solanezumab did not slow the progression of preclinical Alzheimer disease in comparison to placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

Study finds that AI is better at forecasting the risk of developing cancer.

3.

Kate Middleton and Remission: Oncologists Weigh In

4.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

5.

What Role Should Genomic Classifier Testing Play in Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot